期刊文献+

糖尿病肾病合并高血压1例治疗分析 被引量:2

Analysis and treatment of a case of hypertension in patients with diabetic nephropathy
下载PDF
导出
摘要 目的探讨糖尿病肾病合并高血压患者降压药物的合理选择。方法根据患者的全程药学监护,分析1例糖尿病肾病合并高血压患者的药物使用情况。结果血管紧张素受体阻断剂(ARB)+钙通道阻滞剂(CCB)联合用于糖尿病肾病合并高血压,不仅很好地控制了血压,而且延缓了肾病的发展。结论对于糖尿病肾病合并高血压患者的治疗,应首选肾素-血管紧张素-醛固酮系统(RAAS)阻断剂、血管紧张素转换酶抑制剂(ACEI)/ARB,在此基础上可联合CCB或利尿剂,三联用药疗效也较好。 Objective Discussion on reasonable selection of early diabetic nephropathy with hypertension medication of antihypertensive drugs. Methods According to the whole pharmaceutical care for patients, analysis of a case of antihypertensive drugs in patients with diabetic nephropathy usage. Results The combination of ARB+CCB not only for diabetic nephropathy patients with hypertension can develop good blood pressure control can delay renal disease. Conclusion In the treatment of diabetic nephropathy patients with hypertension, should be the preferred RAS blocker ACEIVARB, on this basis can be combined with CCB or diuretics, or triple therapy.
出处 《基层医学论坛》 2013年第14期1772-1774,共3页 The Medical Forum
关键词 糖尿病肾病 高血压 降压药物 临床药师 Diabetic nephmpathy Hypertension Drug therapy Clinical pharmacist
  • 相关文献

参考文献6

二级参考文献27

  • 1李晓东,郭志军,高山林,赵慧娟,张林霞,孙东立.醛固酮及其受体拮抗剂对肾小球系膜细胞转化生长因子β1基因表达的影响[J].中国现代医学杂志,2006,16(13):1937-1940. 被引量:7
  • 2孙爱华,赵强,梅克治,吴同果,陈国伟.螺内酯对慢性心力衰竭患者神经内分泌激素的影响[J].中国心血管杂志,2007,12(1):34-37. 被引量:7
  • 3李建飞,温黎青,赵勤,吴小宁,王芳芳,陈廷波.醛固酮受体拮抗剂对慢性肾脏病蛋白尿的影响[J].中国医学工程,2007,15(5):413-415. 被引量:5
  • 4Burnier M, Roch Ramel F, Burnier HR. Reral offects of angiotensin, II receptor blockade in normoternsive subjects. Kideny Int, 1996,49(5):1787-1790.
  • 5Peralta CA,Hicks LS,Chertow GM,et al.Control of hypertension in adults with chronic kidney disease in the United States[J].Hypertension,2005,45(6):1119-1124.
  • 6Hsu CY,Bates DW,Kuperman G J,et al.Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency[J].Am J Hypertens,2001,14(12):1219-1225.
  • 7Pohl MA,Blumenthal S,Cordonnier DJ,et al.Independent and additive impact of blood pressure control and angiotensin Ⅱ receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial:Clinical implications and limitations[J].J Am Soc Nephrol,2005,16(10):3027-3037.
  • 8Anon.K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease[J].Am J Kidney Dis,2004,43(5 Suppl 1):S1-S290.
  • 9Dworkin LD,Bemtein JA,Palker M,et al.Calcium antagonist and converting enzymeinhibitors reduce renalmjury by diferent mechanisms[J].Kideny Int,1993,43(4):808-814.
  • 10Bakris GL,Hart P,Ritz E.Beta Blockers in the management of chronic kidney disease[J].Kidney Int,2006,70(11):1905-1913.

共引文献19

同被引文献14

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部